Magniject is indicated in the treatment of hypomagnesaemia in cattle and sheep. Hypomagnesaemia is referred to as milk fever.
Active Substance
Magnesium Sulphate Heptahydrate 25.0 % w/v
Target Species
Cattle and Sheep
Treats and Controls
Hypomagnesaemia (Milk Fever).
Application Method
Administer by subcutaneous or slow intravenous injection
Warm to body temperature before administration.
Magniject can be safely administered during pregnancy and lactation.
Withdrawal Period
Meat: zero days.
Milk: zero days.
Dosage
Administer by subcutaneous injection only.
Cattle: Up to 400 ml
Sheep: Up to 75 ml
Key Features of Magniject.
In most cases cows will show some excitement or agitation with a tremor or spasm in muscles of the head and limbs. Then they will often stagger and go down to a "sitting" position, often with a 'kink' in her neck, and finally lie flat on their side before circulatory collapse, coma and even death.
A dry muzzle, staring eyes, cold legs and ears, constipation and drowsiness are seen after going down.
The heart beat becomes weaker and faster.
The body temperature falls below normal, especially in cold, wet, windy weather.
These signs are due mainly to lowered blood calcium levels.
Sometimes there are additional signs due to complicating factors.
Bloat is common in cows unable to "sit up" because the gas in the rumen is unable to escape.
Pneumonia and exposure may affect cows left out in bad weather.
Click here to Download Data Sheet.
Health Products Regulatory Authority
Summary of Product Characteristics
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Magniject 25% Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance:
Magnesium Sulphate Heptahydrate 25.0 % w/v
3 PHARMACEUTICAL FORM
Solution for injection.
4 CLINICAL PARTICULARS
4.1 Target Species
Cattle, Sheep.
4.2 Indications for use, specifying the target species
Magniject is indicated in the treatment of hypomagnesaemia in cattle and sheep.
4.3 Contraindications
Do not administer intravenously.
4.4 Special warnings for each target species
None.
4.5 Special precautions for use
Special precautions for use in animals
Warm to body temperature prior to administration.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
None.
4.6 Adverse reactions (frequency and seriousness)
None known.
4.7 Use during pregnancy, lactation or lay
Magniject can be safely administered during pregnancy and lactation.
4.8 Interaction with other medicinal products and other forms of interactions
None known.
4.9 Amounts to be administered and administration route
Administer by subcutaneous injection only.
Cattle: Up to 400 ml
Sheep: Up to 75 ml
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Not applicable.
4.11 Withdrawal period(s)
Meat: zero days.
Milk: zero days.
5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES
Magniject administered by subcutaneous injection corrects the ionic disturbance that results from hypomagnesaemia.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Hydrochloric Acid Water for Injection
6.2 Major incompatibilities
None known.
6.3 Shelf-life
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.
This product is for single use only.
6.4 Special precautions for storage
Do not store above 25oC.
6.5 Nature and composition of immediate packaging
Magniject, a clear colourless solution, is marketed in either 400 ml Amber Type III glass vials sealed with black rubber wads and aluminium screw caps, or 400 ml polypropylene containers sealed with bromobutyl bungs and aluminium caps.
6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Any unused product or waste material should be disposed of in accordance with national requirements.
7 MARKETING AUTHORISATION HOLDER
Norbrook Laboratories (Ireland) Limited
Rossmore Industrial Estate
Monaghan
Ireland
8 MARKETING AUTHORISATION NUMBER(S)
VPA22664/030/001
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 01 October 1991
Date of last renewal: 01 October 2006
10 DATE OF REVISION OF THE TEXT
Januray 2019
Would you like to send this voucher to the recipient via email?
Yes No
